TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28887751

Group type: EXPERIMENTAL
Intervention: Risky Sex class (n = 72, 28%)
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Low Sexual Risk class (n = 190, 73%)
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Drug-Using, Violence-Exposed, and Impaired Sex class (n = 53; 14%)
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Risky Sex and Moderate Drinking class (n = 326; 86%)
Number of subjects: 641
Study: 28887801

Group type: EXPERIMENTAL
Intervention: Subcutaneous belimumab 200 mg once weekly plus standard of care
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Subcutaneous belimumab 200 mg once weekly
Number of subjects: 687
Study: 28888148

Group type: EXPERIMENTAL
Intervention: T1DM
Number of subjects: 1153

Group type: EXPERIMENTAL
Intervention: T2DM
Number of subjects: 1153

Group type: EXPERIMENTAL
Intervention: T1DM and T2DM
Number of subjects: 1153
Study: 28889107

Group type: EXPERIMENTAL
Intervention: Switching from phosphodiesterase-5 inhibitors (PDE5i) to riociguat
Number of subjects: 0
Study: 28889769

Group type: EXPERIMENTAL
Intervention: Orsiro biodegradable polymer drug-eluting stent (BP-DES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Xience durable polymer drug-eluting stent (DP-DES)
Number of subjects: 0
Study: 28890218

Group type: EXPERIMENTAL
Intervention: Perfluorooctanoic acid (PFOA)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Perfluorohexanesulfonic acid
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: PFOA and perfluorononanoic acid
Number of subjects: 402
Study: 28890439

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28890833

Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Number of subjects: 0
Study: 28891911

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imaging techniques (functional MRI, diffusion tensor imaging, arterial spin labeling)
Number of subjects: 0
Study: 28892085

Group type: EXPERIMENTAL
Intervention: Circulating endothelial cell count (CEC) analysis using the CellSearch system
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: On-demand evaluation of CEC counts
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: CEC changes during allo-HSCT
Number of subjects: 90
Study: 28892218

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg, adjustable to 25 or 100 mg based on efficacy and safety, taken ~1 hour before sexual activity, not more than once daily)
Number of subjects: 997

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 997
Study: 28893304

Group type: EXPERIMENTAL
Intervention: Modulating the host immune system to resist HIV infection (specific intervention details not provided)
Number of subjects: 0
Study: 28893386

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28893549

Group type: EXPERIMENTAL
Intervention: aCRT
Number of subjects: 0

Group type: COMPARATOR
Intervention: convCRT
Number of subjects: 0
Study: 28893761

Group type: EXPERIMENTAL
Intervention: Azithromycin distribution with a coverage target of 90% for 4 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Azithromycin distribution with a coverage target of 80% for 1 day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Comparison of both interventions
Number of subjects: 24
Study: 28893770

Group type: EXPERIMENTAL
Intervention: Absorb bioresorbable vascular scaffold
Number of subjects: 29
Study: 28893779

Group type: EXPERIMENTAL
Intervention: Ceftolozane-tazobactam 1.5 g every 8 hours (q8h)
Number of subjects: 0
Study: 28893813

Group type: EXPERIMENTAL
Intervention: Medicaid-insured visits after ACA implementation in expansion states
Number of subjects: 870319

Group type: EXPERIMENTAL
Intervention: Privately insured visits in nonexpansion states
Number of subjects: 870319

Group type: COMPARATOR
Intervention: Uninsured visits for non-Hispanic white patients in expansion states
Number of subjects: 870319

Group type: COMPARATOR
Intervention: Relative change in uninsured visits between expansion and nonexpansion states
Number of subjects: 870319
Study: 28894606

Group type: EXPERIMENTAL
Intervention: Self-retained cryopreserved amniotic membrane (CAM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional maximum treatment (control)
Number of subjects: 20
Study: 28894792

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow MSCs
Number of subjects: 0
Study: 28898284

Group type: EXPERIMENTAL
Intervention: Isometric exercise for 6 minutes
Number of subjects: 27
Study: 28898890

Group type: EXPERIMENTAL
Intervention: Pirfenidone, mean daily dose of 2,091.1 mg, mean exposure of 122 weeks (SD 98), median exposure of 88 weeks (range >0 to 349 weeks)
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 1058
Study: 28899363

Group type: EXPERIMENTAL
Intervention: LJM716 40 mg/kg QW
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: LJM716
Number of subjects: 54
Study: 28899394

Group type: EXPERIMENTAL
Intervention: Peer support intervention for reentry veterans
Number of subjects: 600000
Study: 28899434

Group type: EXPERIMENTAL
Intervention: Care Group model with social and behavior change communication (SBCC)
Number of subjects: 0
Study: 28899517

Group type: EXPERIMENTAL
Intervention: Surgical treatment of OSA
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) treatment of OSA
Number of subjects: 113

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 113

Group type: COMPARATOR
Intervention: Dietary intervention
Number of subjects: 113
Study: 28899825

Group type: EXPERIMENTAL
Intervention: Implanted neuroprostheses (NPs) for lower extremity function
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: First-generation implanted pulse generator (IPG) and epimysial electrodes
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Second-generation IPG along with intramuscular and nerve cuff electrodes
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Technical and clinical performance of implanted LE NPs
Number of subjects: 22
Study: 28900040

Group type: EXPERIMENTAL
Intervention: Citric acid nebulization (2.8 mol/L)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (stroke subjects without dysphagia or aspiration)
Number of subjects: 42
Study: 28900041

Group type: EXPERIMENTAL
Intervention: Cough Peak Flow (CPF) measured using a ventilator flow meter before extubation
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Cough Peak Flow (CPF) measured using a ventilator flow meter
Number of subjects: 92
Study: 28900115

Group type: EXPERIMENTAL
Intervention: ADI-PEG20
Number of subjects: 43
Study: 28900544

Group type: EXPERIMENTAL
Intervention: Aspira-aA (Human Optics)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tecnis ZCB00 (Abbott Medical Optics)
Number of subjects: 60
Study: 28900714

Group type: EXPERIMENTAL
Intervention: peginterferon alpha-2a (PEGASYS®, 180 µg/week) plus ribavirin (COPEGUS®, 1000/1200 mg/day in genotypes (GT) 1/4 and 800 mg/day in GT 2/3) for 24-72 weeks
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 88
Study: 28900875

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly for 24 weeks
Number of subjects: 85
Study: 28902596

Group type: EXPERIMENTAL
Intervention: Investigational assay for detecting resistance to isoniazid
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Investigational assay for detecting resistance to ofloxacin
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Investigational assay for detecting resistance to moxifloxacin at 0.5 μg/mL
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Investigational assay for detecting resistance to moxifloxacin at 2.0 μg/mL
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Investigational assay for detecting resistance to kanamycin
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Investigational assay for detecting resistance to amikacin
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Investigational assay for detecting resistance to isoniazid using DNA sequencing
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Investigational assay for detecting resistance to fluoroquinolones using DNA sequencing
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Investigational assay for detecting resistance to kanamycin using DNA sequencing
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Investigational assay for detecting resistance to amikacin using DNA sequencing
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Investigational assay for detecting phenotypic resistance
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Investigational assay for detecting resistance using DNA sequencing
Number of subjects: 308
Study: 28903892

Group type: EXPERIMENTAL
Intervention: SmartMoms intervention (in-person)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: SmartMoms intervention (remote)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Remote intervention cost
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: In-person intervention cost
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Intervention adherence (SmartMoms)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Intervention adherence (Usual care)
Number of subjects: 54
Study: 28903941

Group type: EXPERIMENTAL
Intervention: Insulin provision (IP) therapy
Number of subjects: 295

Group type: COMPARATOR
Intervention: Insulin sensitization (IS) therapy
Number of subjects: 295
Study: 28903943

Group type: EXPERIMENTAL
Intervention: SGN-CD19B at a dose of 300 μg/kg (3 μg/kg drug equivalents)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SGN-CD19B in combination with rituximab at a dose of 100 μg/kg (1 μg/kg drug equivalents)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SGN-CD19B
Number of subjects: 0
Study: 28905294

Group type: EXPERIMENTAL
Intervention: Methyl aminolevulinate cream (MAL) daylight photodynamic therapy (DL-PDT)
Number of subjects: 81
Study: 28905323

Group type: EXPERIMENTAL
Intervention: 5-azacitidine (75 mg/m²)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: panobinostat and 5-azacitidine
Number of subjects: 0
Study: 28910851

Group type: EXPERIMENTAL
Intervention: Hemostatic powder
Number of subjects: 44
Study: 28911072

Group type: EXPERIMENTAL
Intervention: MSK-IMPACT genomic profiling
Number of subjects: 1932
Study: 28911136

Group type: EXPERIMENTAL
Intervention: Pork ingestion (170 g) in the OB group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pork ingestion (170 g) in the NW group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pork ingestion (170 g) in the OW group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Basal MPS
Number of subjects: 30
Study: 28911148

Group type: EXPERIMENTAL
Intervention: Young lean individuals (YL)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Older lean individuals (OL)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Older obese individuals (OO)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Young lean individuals (YL) vs Older lean individuals (OL)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Young lean individuals (YL) vs Older obese individuals (OO)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Older obese individuals (OO) vs Older lean individuals (OL)
Number of subjects: 35
Study: 28911152

Group type: EXPERIMENTAL
Intervention: Hypoglycemia preconditioning
Number of subjects: 13

Group type: COMPARATOR
Intervention: Euglycemia preconditioning
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: HAAF induction
Number of subjects: 13
Study: 28911517

Group type: EXPERIMENTAL
Intervention: FDA Regulatory Approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0/1-h Algorithm for Rapid Diagnosis of MI
Number of subjects: 0
Study: 28911922

Group type: EXPERIMENTAL
Intervention: Sorafenib 400mg q12h daily combined with gemcitabine and cisplatin (SGC)
Number of subjects: 46
Study: 28912030

Group type: EXPERIMENTAL
Intervention: Remnant indocyanine green clearance rate using galactosyl (KGSA)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Post-hepatectomy liver failure definitions
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: 90-day mortality rate
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Overall morbidity rate
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Median hospital stay
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Median ICU stay
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: 90-day major complication and mortality rates
Number of subjects: 185
Study: 28912187

Group type: EXPERIMENTAL
Intervention: Dilated cardiomyopathy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypertrophic cardiomyopathy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General pediatric cardiomyopathies
Number of subjects: 0
Study: 28912376

Group type: EXPERIMENTAL
Intervention: BAX 930 (recombinant ADAMTS-13) at doses of 5, 20, or 40 U/kg body weight
Number of subjects: 15
Study: 28912629

Group type: EXPERIMENTAL
Intervention: Multiple spinal manipulations administered in a single session
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28912804

Group type: EXPERIMENTAL
Intervention: Nutritional assessment
Number of subjects: 16
Study: 28912956

Group type: EXPERIMENTAL
Intervention: SRT2104 (2.0 g/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 28913744

Group type: EXPERIMENTAL
Intervention: Children with ADHD
Number of subjects: 392

Group type: COMPARATOR
Intervention: Local normative (non-ADHD) comparison group
Number of subjects: 392
Study: 28913922

Group type: EXPERIMENTAL
Intervention: Hydroxyurea at maximal tolerated dose (MTD)
Number of subjects: 230

Group type: COMPARATOR
Intervention: HbF% values ≤20%
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Hydroxyurea therapy
Number of subjects: 230
Study: 28914600

Group type: EXPERIMENTAL
Intervention: Injected fluorine 18
Number of subjects: 0
Study: 28915798

Group type: EXPERIMENTAL
Intervention: Vemurafenib plus cobimetinib
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard response assessment with RECISTv1.1 ceCT at 7 weeks
Number of subjects: 90
Study: 28915825

Group type: EXPERIMENTAL
Intervention: Mobile app intervention
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 135
Study: 28915844

Group type: EXPERIMENTAL
Intervention: Incentive plus Restriction
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Restriction
Number of subjects: 279
Study: 28915862

Group type: EXPERIMENTAL
Intervention: Brief education on pulse palpation focusing on evaluating rhythm regularity
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 205
Study: 28915898

Group type: EXPERIMENTAL
Intervention: HEMS
Number of subjects: 266

Group type: COMPARATOR
Intervention: EMS
Number of subjects: 266
Study: 28916584

Group type: EXPERIMENTAL
Intervention: Low VWF levels (30-50 IU/dL)
Number of subjects: 126
Study: 28916600

Group type: EXPERIMENTAL
Intervention: Higher white blood cell count (WBC)
Number of subjects: 4222

Group type: COMPARATOR
Intervention: Lower white blood cell count (WBC)
Number of subjects: 4222
Study: 28916602

Group type: EXPERIMENTAL
Intervention: Angiography-derived FFR measurements
Number of subjects: 0
Study: 28916953

Group type: EXPERIMENTAL
Intervention: 30-mg dexlansoprazole
Number of subjects: 104
Study: 28916979

Group type: EXPERIMENTAL
Intervention: P4HB bioresorbable mesh
Number of subjects: 31
Study: 28917612

Group type: EXPERIMENTAL
Intervention: Thyroid-stimulating hormone level >2.5 mIU/L
Number of subjects: 1193

Group type: EXPERIMENTAL
Intervention: Presence of thyroid antibodies
Number of subjects: 1193
Study: 28917644

Group type: EXPERIMENTAL
Intervention: ALPPS procedure
Number of subjects: 20
Study: 28917648

Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine/bevacizumab with or without oxaliplatin (mFOLFOX7 or XELOX) as first line chemotherapy for metastatic colorectal cancer
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine (physician choice: 5-FU/LV or capecitabine)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 32
Study: 28917673

Group type: EXPERIMENTAL
Intervention: Group A (n=27)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Group B (n=39)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Group C (n=32)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: hsTnT ≥15 ng/l (n=29) in Group B
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: BNP ≥550 pg/ml (n=10) in Group B
Number of subjects: 98
Study: 28917674

Group type: EXPERIMENTAL
Intervention: Coronary artery calcium score (CACS)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CTA)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Single-photon emission computed tomography (SPECT)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Invasive coronary angiography (ICA)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Traditional risk factors
Number of subjects: 154
Study: 28918167

Group type: EXPERIMENTAL
Intervention: BMI/%WL equal or higher than grade 3
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: PG-SGA classified as malnutrition
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Low skeletal muscle mass
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Low muscle mass plus low muscle strength
Number of subjects: 84

Group type: COMPARATOR
Intervention: Low muscle strength alone
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Low muscle mass in combination with low strength
Number of subjects: 84
Study: 28918186

Group type: EXPERIMENTAL
Intervention: Melanoma-related limb lymphoedema present (109 patients)
Number of subjects: 431

Group type: COMPARATOR
Intervention: No lymphoedema (322 patients)
Number of subjects: 431
Study: 28918401

Group type: EXPERIMENTAL
Intervention: Return to work after ARDS
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Delayed return to work
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Lost earnings
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Healthcare coverage
Number of subjects: 138
Study: 28918414

Group type: EXPERIMENTAL
Intervention: Innovative online tool for peer review
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual peer reviewer process
Number of subjects: 0
Study: 28918441

Group type: EXPERIMENTAL
Intervention: LSD (200 μg)
Number of subjects: 16
Study: 28918456

Group type: EXPERIMENTAL
Intervention: 28-day self-paced smartphone-delivered mindful eating intervention
Number of subjects: 104
Study: 28919031

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) injection for fluorescence detection of sentinel lymph nodes (SLN)
Number of subjects: 30
Study: 28919454

Group type: EXPERIMENTAL
Intervention: Abagovomab (anti-idiotypic monoclonal antibody mimicking the CA125 protein) vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28919776

Group type: EXPERIMENTAL
Intervention: Omaveloxolone (15 mg orally once daily)
Number of subjects: 0
Study: 28921760

Group type: EXPERIMENTAL
Intervention: Genome-wide SNP genotyping
Number of subjects: 954
Study: 28921872

Group type: EXPERIMENTAL
Intervention: Dacomitinib 45 mg/day, orally, continuously
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Dacomitinib
Number of subjects: 28
Study: 28921907

Group type: EXPERIMENTAL
Intervention: Trametinib and GSK2141795
Number of subjects: 0
Study: 28922088

Group type: EXPERIMENTAL
Intervention: Perfluorohexyloctane, 1 drop, 4 times daily for 6-8 weeks
Number of subjects: 72
Study: 28922337

Group type: EXPERIMENTAL
Intervention: Use of the internet to find information about health
Number of subjects: 3161

Group type: EXPERIMENTAL
Intervention: Use of the internet to find information about surgery
Number of subjects: 3161

Group type: EXPERIMENTAL
Intervention: Use of the internet to find specific information about anaesthesia
Number of subjects: 3161

Group type: EXPERIMENTAL
Intervention: Difficulty searching for appropriate information about anaesthesia on the internet
Number of subjects: 3161

Group type: EXPERIMENTAL
Intervention: Daily use of the web
Number of subjects: 3161

Group type: EXPERIMENTAL
Intervention: Use of the web on mobile devices
Number of subjects: 3161

Group type: EXPERIMENTAL
Intervention: Asking general practitioner or surgeon about information
Number of subjects: 3161
Study: 28922466

Group type: EXPERIMENTAL
Intervention: Blinatumomab (continuous intravenous infusion)
Number of subjects: 189
Study: 28923027

Group type: EXPERIMENTAL
Intervention: Aesthetic principles access (APA)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Minimally invasive access (MIA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional access (CA)
Number of subjects: 120
Study: 28923034

Group type: EXPERIMENTAL
Intervention: Women's Health CoOp (WHC) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 28923060

Group type: EXPERIMENTAL
Intervention: Vitamin-D deficiency (<10 ng/ml)
Number of subjects: 960
Study: 28923104

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) administration of enadenotucirev
Number of subjects: 17

Group type: COMPARATOR
Intervention: Intratumoral (IT) injection of enadenotucirev (CRC only)
Number of subjects: 17
Study: 28923290

Group type: EXPERIMENTAL
Intervention: Liquid formulation of Kaletra (lopinavir/ritonavir)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Taste stimuli including common excipients (ethanol, denatonium)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genotype-phenotype relationships
Number of subjects: 0
Study: 28923760

Group type: EXPERIMENTAL
Intervention: Chronic Respiratory Disease Questionnaire
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Feeling Thermometer
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: LASA Physical Activity Questionnaire (LAPAQ)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: BODEx index with LAPAQ added
Number of subjects: 408
Study: 28923789

Group type: EXPERIMENTAL
Intervention: AZD4017
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30